Biography – Roni H. Amiel

Elected by “Becker’s Hospital Review” to be in the Top 100 CIOs and other executive-level information technology leaders from hospitals and health systems across the country. Who ¬†demonstrated excellence in leadership by tackling the challenging world of health IT and innovating during a time of change in the industry.¬†

http://www.beckershospitalreview.com/100-hospital-and-health-system-cios-to-know-2015.html

¬†Roni Amiel is currently the Chief Information Officer (CIO) and Chief Information Security Officer (CISO) at the Blythedale Children’s Hospital, a position he has held since 2011. Previously, he was the CIO/CISO for the office of the Chief Medical Examiner of the City of New York’s Department of Health (2009-2012). Mr. Amiel is also the Chairman of the Outcomes & Research Committee at International Pediatric Rehabilitation Collaborative (IPRC) and a part-time Writer \ Contributor of Executive Insight Healthcare Magazine.

Roni have transformed the organization in the way clinical and administrative information is captured, reported, analyzed and acted on. Spearheading a robust infrastructure that allow actionable information in real time. Development of applications that bridge the gaps between EMR and clinical workflow. Roni is taking these practices that were developed in the last 4 years and applying them with large hospitals.

In prior roles, he was a Chief Architect and Technology Advisor for Immugen Pharmaceutical (2010-2011), where he assessed the company’s technology strategies and made recommendations to help direct technical research activities. Mr. Amiel was also the Principal and Cofounder of Novolutions Inc (2008-2009), a hi-tech security device provider that utilizes GPS and cellular base technology. He also worked as the Director of Information Systems at Columbia University’s Cardiovascular Research Foundation (2005-2008) and a Senior Director of Information Systems at PTC Therapeutics (2000-2005), a biopharmaceutical company focused on the development of orally administered proprietary small-molecule drugs that target post-transcriptional control processes.

He holds degrees and has completed academic programs in Information Technology, Business Strategy, Executive Leadership, Project Management, and Finance from NYU and Colorado Technical University.

. Linkedin Profile.